Massive japanese study checks kidney Drug's Real-World safety
NCT ID NCT02847624
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This study followed 1,802 people in Japan with autosomal dominant polycystic kidney disease (ADPKD) who were taking the drug tolvaptan. Researchers wanted to see how safe and effective the drug is in everyday medical practice, not just in controlled trials. They measured changes in total kidney volume over time and tracked liver enzyme levels to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.